Business Description
Castle Biosciences Inc
NAICS : 621511
SIC : 8071
ISIN : US14843C1053
Description
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 10.46 | |||||
| Equity-to-Asset | 0.86 | |||||
| Debt-to-Equity | 0.06 | |||||
| Debt-to-EBITDA | 1.07 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 8.43 | |||||
| Beneish M-Score | -2.63 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 35.3 | |||||
| 3-Year EBITDA Growth Rate | -64.9 | |||||
| 3-Year EPS without NRI Growth Rate | -63.9 | |||||
| 3-Year Book Growth Rate | -5.2 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 8.21 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 31.04 | |||||
| 9-Day RSI | 41.61 | |||||
| 14-Day RSI | 47.06 | |||||
| 6-1 Month Momentum % | 20.63 | |||||
| 12-1 Month Momentum % | 63.24 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.78 | |||||
| Quick Ratio | 7.64 | |||||
| Cash Ratio | 6.32 | |||||
| Days Inventory | 46.48 | |||||
| Days Sales Outstanding | 50.15 | |||||
| Days Payable | 55.44 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.4 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 81.9 | |||||
| Operating Margin % | -0.33 | |||||
| Net Margin % | 1.95 | |||||
| FCF Margin % | 11.07 | |||||
| ROE % | 1.49 | |||||
| ROA % | 1.29 | |||||
| ROIC % | -0.28 | |||||
| 3-Year ROIIC % | -36.6 | |||||
| ROC (Joel Greenblatt) % | 18.49 | |||||
| ROCE % | 2.7 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Price-to-Owner-Earnings | 125.8 | |||||
| PS Ratio | 2.96 | |||||
| PB Ratio | 1.98 | |||||
| Price-to-Tangible-Book | 2.64 | |||||
| Price-to-Free-Cash-Flow | 45.69 | |||||
| Price-to-Operating-Cash-Flow | 15.75 | |||||
| EV-to-EBIT | -183.91 | |||||
| EV-to-Forward-EBIT | -11.07 | |||||
| EV-to-EBITDA | 73.29 | |||||
| EV-to-Revenue | 2.38 | |||||
| EV-to-Forward-Revenue | 2.66 | |||||
| EV-to-FCF | 20.23 | |||||
| Price-to-Projected-FCF | 4.52 | |||||
| Price-to-Net-Current-Asset-Value | 3.21 | |||||
| Price-to-Net-Cash | 4.23 | |||||
| Earnings Yield (Greenblatt) % | -0.54 | |||||
| FCF Yield % | 2.33 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CSTL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Castle Biosciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 311.878 | ||
| EPS (TTM) ($) | 0.21 | ||
| Beta | 1.25 | ||
| Volatility % | 51.52 | ||
| 14-Day RSI | 47.06 | ||
| 14-Day ATR ($) | 1.818542 | ||
| 20-Day SMA ($) | 32.406 | ||
| 12-1 Month Momentum % | 63.24 | ||
| 52-Week Range ($) | 16.2 - 35.84 | ||
| Shares Outstanding (Mil) | 27.74 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Castle Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Castle Biosciences Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Castle Biosciences Inc Frequently Asked Questions
What is Castle Biosciences Inc(CSTL)'s stock price today?
The current price of CSTL is $31.15. The 52 week high of CSTL is $35.84 and 52 week low is $16.20.
When is next earnings date of Castle Biosciences Inc(CSTL)?
The next earnings date of Castle Biosciences Inc(CSTL) is 2024-11-04.
Does Castle Biosciences Inc(CSTL) pay dividends? If so, how much?
Castle Biosciences Inc(CSTL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers